Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Adjuvant S-1 and Oxaliplatin (SOX) in Esophageal Cancer
NCT02347904Phase 1Completed
- Sponsor
- University of Amsterdam
- Start
- Dec 2014
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegafur in esophageal cancer, sponsored by University of Amsterdam. Primary endpoint: Percentage of patients completing the preplanned number of 6 cycles of SOX at 24 months. Started Dec 2014; status: completed.
02
Drugs
tegafur
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02347904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347904.